Please assess the completion status of the following clinical trial:

Trial Title: Carbohydrate Antigen 125-guided Therapy in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* At least 1 admission for AHF, in the last 180 days.~* Demonstrates functional New York Heart Association status of Class ≥II at the moment of enrollment.~* Objective evidence, either during the index admission or at least 180 days before enrollment, of a structural or functional abnormality of the heart at rest, and defined as: N terminal-pro-brain natriuretic peptide \>1000 pg/ml or brain natriuretic peptide \>100 pg/ml or echocardiographic abnormalities congruent with HF diagnosis such as: systolic left ventricular dysfunction (LVEF \<50%); left ventricular hypertrophy (defined as left ventricular septum or left ventricular posterior wall thickness ≥12 millimeters or left ventricular mass index \>104 g/m2 in women or 116 g/m2 in men); Ee'\>15 or significant valvular heart disease (moderate-severe).~* A plasma CA125 value \>35 U/ml in a recent test evaluation (at least 30 days before enrollment, and preferably assessed before hospital discharge).~* Patient must be capable of understanding and signing an informed consent form.~Exclusion Criteria:~* Life expectancy \<12 months due to other diseases different from HF.~* Having undergone a cardiac transplantation, coronary revascularization procedure (percutaneous coronary intervention and/or coronary artery bypass grafting) or cardiac valve replacement in the past 3 months.~* Angina pectoris higher than class II (Canadian Cardiovascular Society Classification).~* Pregnancy at the moment of enrollment.~* Valvular heart disease already scheduled for surgical intervention.~* Severe chronic obstructive and/or restrictive pulmonary disease, requiring continuous oxygen administration.~* Serum creatinine level \> 3 mg/dl or chronic renal insufficiency on dialysis treatment.~* Patients receiving resynchronization therapy during the index admission.~* Significant concurrent medical diseases including cancer or a history of cancer within 5 years of entering the screening period, endometriosis, cirrhosis, acute coronary syndrome within 6 months, uncontrolled hypertension, history of human immunodeficiency virus (HIV) infection, or a significant active infection.~* Participating in another randomized study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CA125 guided strategy (Type: EXPERIMENTAL): In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
- Standard treatment strategy (Type: ACTIVE_COMPARATOR): Therapy is based on established european current guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).